SCHEMBL4674434

SCHEMBL4674434

O=C(C=C(O)c1nc[nH]n1)c1cc(S(=O)(=O)c2ccc(Cl)cc2)n[nH]1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.41
GAA P10253 1/20 0.35
KDM4E B2RXH2 2/20 0.34
PKM P14618 1/20 0.34
CA12 O43570 1/20 0.33
ALPL P05186 1/20 0.33
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NAMPT P43490 3/20 0.32
MAPT P10636 3/20 0.31
ALDH1A1 P00352 2/20 0.31
CYP3A4 P08684 1/20 0.31
MAPK1 P28482 1/20 0.31
CHEK2 O96017 1/20 0.31
TP53 P04637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
PTPN1 P18031 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674048 0.89 AKR1B1 (0.41) AKR1B1CA12ALPLNAMPT
SCHEMBL4675743 0.83 AKR1B1 (0.41) AKR1B1GAAKDM4EPKMCA12
SCHEMBL4674703 0.81 AKR1B1 (0.47) AKR1B1GAAKDM4EPKMCA12
SCHEMBL4671593 0.80 AKR1B1 (0.34) AKR1B1KDM4EPKMSMN1; SMN2NAMPT
SCHEMBL4672028 0.79 AKR1B1 (0.34) AKR1B1KDM4EPKMHTTSMN1; SMN2
SCHEMBL4677186 0.78 ALDH1A1 (0.33) AKR1B1SMN1; SMN2NAMPTMAPTALDH1A1
SCHEMBL4680017 0.78 ALDH1A1 (0.33) AKR1B1HTTSMN1; SMN2NAMPTMAPT
SCHEMBL4679590 0.77 CHEK2 (0.32) AKR1B1SMN1; SMN2ALDH1A1CYP3A4MAPK1
SCHEMBL4678455 0.77 CHEK2 (0.32) AKR1B1GAASMN1; SMN2ALDH1A1CYP3A4
SCHEMBL4677447 0.77 LMNA (0.35) AKR1B1SMN1; SMN2NAMPTALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AKR1B1 17/4885GAA 1884/4885KDM4E 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.